Teva reported Thursday that sales for the quarter ended June 30 were $5 billion, 19% more than sales for the same period last year, which held at $4.2 billion. US sales climbed 28% to $2.5 billion, with generics contributing just over $1 billion in sales and branded drugs added $1.3 billion to the US quarterly sales tally. Generic sales slipped 12% in Europe, to $884 million, compared to almost $1 billion in sales for the same period the year before. Europe embraced branded drugs to a larger extent this quarter, with $402 million in sales, a 46% of increase of sales during the same period last year. President and CEO Jeremy Levin said in a statement that the company is on track to meet the year's financial goals. Credit Suisse analyst Michael Faerm said in a research note that the results missed consensus estimates for sales that but operating expenses were well below expectations.
Everyday Health reported that advertising and sponsorship from healthcare companies grew 35% when compared to the first six months of 2011. The privately held firm, whose media portfolio includes a mix of video, mobile and social touchpoints, said revenue from its top 20 advertisers grew 31% for the first half of 2012, compared to the same period in 2011. The previously text-centric health information firm has undergone rapid changes, including the December launch of a video channel on YouTube, last September's TV series debut and the August 2011 hiring of SVP/GM Paul Slavin. The company has 25 digital health and life properties in the US and is increasing is global reach -- it announced in July that it was breaking into the UK with its first site, WhattoExpect.co.uk, in November and plans to launch EverydayHealth.co.uk in 2013.